{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:05:24Z","timestamp":1773752724171,"version":"3.50.1"},"reference-count":36,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mem. Inst. Oswaldo Cruz"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1590\/0074-02760150390","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T17:32:58Z","timestamp":1460223178000},"page":"252-257","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil"],"prefix":"10.1590","volume":"111","author":[{"given":"Camila V","family":"Pereira","sequence":"first","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane Valle","family":"Tovo","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago K","family":"Grossmann","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique","family":"Mirenda","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna B","family":"Dal-Pupo","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo RL de","family":"Almeida","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo A de","family":"Mattos","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C","volume":"24","author":"Bedossa P","year":"1996","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1111\/liv.12392","article-title":"HBeAg-positive chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogs?","volume":"34","author":"Buti M","year":"2014","journal-title":"Liver Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MEG.0b013e3283511287","article-title":"Efficacy and safety of entecavir in clinical practice in treatment-na\u00efve Caucasian chronic hepatitis B patients","volume":"24","author":"Buti M","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang TT","year":"2006","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jhep.2014.02.013","article-title":"Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation","volume":"60","author":"Chen C","year":"2014","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3748\/wjg.v19.i5.721","article-title":"Australian tertiary care outcomes of entecavir monotherapy in treatment-na\u00efve patients with chronic hepatitis B","volume":"19","author":"Fahrtash-Bahin F","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-13-181","article-title":"Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening","volume":"13","author":"Hahn\u00e9 SJ","year":"2013","journal-title":"BMC Infect Dis"},{"key":"ref9","article-title":"Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection - a systematic review and meta-analysis","volume":"9","author":"Ke W","year":"2014","journal-title":"PLoS ONE"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai CL","year":"2006","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1128\/AAC.03845-14","article-title":"Efficacy of entecavir plus tnofovir combination therapy for chronic hepatitis B patients with multi-drug resistant strains","volume":"58","author":"Lee YB","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/liv.12057","article-title":"Impact of therapy on the outcome of chronic hepatitis B","volume":"33","author":"Liaw YF","year":"2013","journal-title":"Liver Int"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jgh.12108","article-title":"Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice","volume":"28","author":"Lin B","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jfma.2013.02.001","article-title":"Hepatitis B viral factors and treatment responses in chronic hepatitis B","volume":"112","author":"Lin C","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MEG.0b013e32835b3677","article-title":"Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice","volume":"25","author":"Liu A","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7150\/ijms.5472","article-title":"Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-na\u00efve chronic hepatitis B patients in real life","volume":"10","author":"Luo J","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin P","year":"2013","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxilfumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin P","year":"2008","journal-title":"N Engl J Med"},{"key":"ref19","series-title":"Portaria n. 2.561. Protocolo cl\u00ednico e diretrizes terap\u00eauticas - hepatite viral cr\u00f4nica B e coinfec\u00e7\u00f5es","year":"2009"},{"key":"ref20","series-title":"Estudo de preval\u00eancia de base populacional das infec\u00e7\u00f5es pelo v\u00edrus das hepatites A, B e C nas capitais do Brasil (2010)","year":"2010"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","article-title":"Long-term continuous entecavir therapy in nucleos(t)ide-na\u00efve chronic hepatitis B patients","volume":"57","author":"Ono A","year":"2012","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000000099","article-title":"First-line monotherapy of tenofovir or entecavir have comparable efficacies in hepatitis B treatment","volume":"26","author":"Ozaras R","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref23","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings","volume":"9","author":"Pan CQ","year":"2014","journal-title":"PLoS ONE"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2011.09.018","article-title":"Entecavir plus Tenofovir combination as rescue therapy in pre-treated chronic B patients: an international multicenter cohort study","volume":"56","author":"Petersen J","year":"2012","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.3748\/wjg.v20.i23.7169","article-title":"Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir","volume":"20","author":"Ridruejo E","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1665-2681(19)30861-0","article-title":"Efficacy and safety of long term entecavir in chronic hepatitis B treatment na\u00efve patients in clinical practice","volume":"13","author":"Ridruejo E","year":"2014","journal-title":"Ann Hepatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1423-0410.2001.00003.x","article-title":"An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques","volume":"80","author":"Saldanha J","year":"2001","journal-title":"Vox Sang"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jhep.2013.06.007","article-title":"Pattern of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment","volume":"59","author":"Seto W","year":"2013","journal-title":"J Hepatol"},{"key":"ref29","first-page":"143","article-title":"Distribui\u00e7\u00e3o da hepatite B no Brasil: atualiza\u00e7\u00e3o do mapa epidemiol\u00f3gico e proposi\u00e7\u00f5es para seu controle","volume":"18","author":"Souto FJD","year":"1999","journal-title":"Gastroenterol Endosc Digest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney DJ","year":"2009","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jgh.12436","article-title":"Comparing the efficacy and clinical outcome of telbivudine and entecavir na\u00efve patients with hepatitis B virus-related compensated cirrhosis","volume":"29","author":"Tsai M","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jac\/dkr495","article-title":"A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice","volume":"67","author":"Tsai MC","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/liv.12074","article-title":"Treatment of HBV related cirrhosis","volume":"33","author":"Van Bommel F","year":"2013","journal-title":"Liver Int"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1440-1746.2012.07269.x","article-title":"Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir","volume":"28","author":"Wang CC","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"12039","DOI":"10.3748\/wjg.v20.i34.12039","article-title":"Hepatitis B viral load affects prognosis of hepatocellular carcinoma","volume":"20","author":"Yu SJ","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of na\u00efve patients with a partial virological response","volume":"54","author":"Zoutendijk R","year":"2011","journal-title":"Hepatology"}],"container-title":["Mem\u00f3rias do Instituto Oswaldo Cruz"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/mioc\/v111n4\/0074-0276-mioc-111-004-0252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T07:40:58Z","timestamp":1567755658000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0074-02762016000400252&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0074-02762016000400252"],"URL":"https:\/\/doi.org\/10.1590\/0074-02760150390","relation":{},"ISSN":["0074-0276"],"issn-type":[{"value":"0074-0276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}